Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Phase 1 Completed 48 enrolled National Institute of Allergy and Infectious Diseases (NIAID)

RandomizedParallel-groupDouble-blindPrevention

Summary

An effective vaccine may be the only way to stop the HIV pandemic. The purpose of this study is to determine the safety of and immune response to the DNA vaccine, PENNVAX-B with or without an IL-12 adjuvant when given using electroporation.

Timeline

Start: 2009-11
Primary completion: 2011-02
Completion: 2011-03

Publications

Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine. 2015 May 11;33(20):2347-53. doi: 10.1016/j.vaccine.2015.03.036. Epub 2015 Mar 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PENNVAX-B	Vaccine	3 mg	Other
Subject	interleukin-12	Protein / enzyme biologic	1 mg	Other

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Summary

Timeline

Publications

Drugs

Indications